Form 4: Akero Therapeutics Director Judy Chou Receives Equity Grant of 9,398 Restricted Stock Units

Akero Therapeutics, Inc. director Judy Chou was granted 9,398 shares of common stock in the form of Restricted Stock Units (RSUs) as part of her compensation.

Summary

• Judy Chou, a Director at Akero Therapeutics, Inc. (AKRO), acquired 9,398 shares of common stock on June 3, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs), with a transaction price of $0 per share, indicating a grant rather than a purchase.
• Each RSU represents a contingent right to receive one share of Akero Therapeutics Common Stock.
• These RSUs are scheduled to vest in full on the earlier of June 3, 2026, or the date of the Company's next annual meeting of stockholders, contingent upon Ms. Chou's continued service on the Board.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments. It's a standard compensation event.

Positives

• The grant of Restricted Stock Units to Director Judy Chou aligns her financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for non-employee directors, reflecting a common corporate governance approach to attract and retain qualified board members.

Future Outlook

The vesting schedule of the RSUs indicates an expectation of continued service from Director Judy Chou on the Board of Akero Therapeutics, aligning her future compensation with the company's performance over the vesting period.

Industry Context

The granting of Restricted Stock Units (RSUs) to non-employee directors is a common practice across the biotechnology and pharmaceutical industries, serving as a key component of director compensation packages designed to align board members' interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of RSUs for director compensation is a standard practice in the biotechnology sector, comparable to compensation structures observed at companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity grants to incentivize their board members.
• The vesting schedule, tied to continued service and a specific future date or the next annual meeting, is also a typical arrangement for such grants, ensuring ongoing commitment from the director.

Corporate Governance

Related Party Transactions

• The RSU grant to Director Judy Chou constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The RSUs granted to Judy Chou will vest on the earlier of June 3, 2026, or the next annual meeting of the Company's stockholders, subject to her continued service.

Key Dates

Keywords

Akero Therapeutics, AKRO, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership